ChiCTR2200066076 版本V1.1 版本创建时间2023/08/10 11:37:21 中国临床试验注册中心

审核状态:

Project audit state:

通过审核

Successful

注册号:

Registration number:

ChiCTR2200066076 

最近更新日期:

Date of Last Refreshed on:

2022-11-23 16:31:29 

注册时间:

Date of Registration:

2022-11-23 00:00:00 

注册号状态:

预注册

Registration Status:

Prospective registration

注册题目:

电针治疗苯二氮卓类药物依赖性失眠的临床随机对照研究

Public title:

Effect of electroacupuncture on insomnia in patients With Dependence of benzodiazepines : a randomized controlled clinical trial

注册题目简写:

English Acronym:

研究课题的正式科学名称:

电针治疗苯二氮卓类药物依赖性失眠的临床随机对照研究

Scientific title:

Effect of electroacupuncture on insomnia in patients With Dependence of benzodiazepines : a randomized controlled clinical trial

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

邱晓玲 

研究负责人:

邱晓玲 

Applicant:

xiaoling qiu 

Study leader:

xiaoling Qiu 

申请注册联系人电话:

Applicant telephone:

13524171629

研究负责人电话:

Study leader's
telephone:

13524171629

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

867171481@qq.com

研究负责人电子邮件:

Study leader's E-mail:

867171481@qq.com

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

上海市浦东新区拱乐路2759号

研究负责人通讯地址:

上海市浦东新区拱乐路2759号

Applicant address:

2759 Gongle Road, Pudong New Area, Shanghai

Study leader's address:

2759 Gongle Road, Pudong New Area, Shanghai

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

上海市浦东新区南汇精神卫生中心

Applicant's institution:

Nanhui mental health center of Shanghai Pudong New Area

研究负责人所在单位:

上海市浦东新区南汇精神卫生中心

Affiliation of the Leader:

Nanhui mental health center of Shanghai Pudong New Area

是否获伦理委员会批准:

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

2022-C-008-E08

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件View

批准本研究的伦理委员会名称:

上海市浦东新区南汇精神卫生中心伦理委员会

Name of the ethic committee:

Ethics Committee of Nanhui mental health center, Pudong New Area, Shanghai

伦理委员会批准日期:

Date of approved by ethic committee:

2022-08-22 00:00:00

伦理委员会联系人:

袁勤

Contact Name of the ethic committee:

qin Yuan

伦理委员会联系地址:

上海市浦东新区拱乐路2759号

Contact Address of the ethic committee:

2759 Gongle Road, Pudong New Area, Shanghai

伦理委员会联系人电话:

Contact phone of the ethic committee:

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

上海市浦东新区南汇精神卫生中心

Primary sponsor:

Nanhui mental health center of Shanghai Pudong New Area

研究实施负责(组长)单位地址:

上海市浦东新区拱乐路2759号

Primary sponsor's address:

2759 Gongle Road, Pudong New Area, Shanghai

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

上海市

市(区县):

Country:

China

Province:

Shang'hai

City:

单位(医院):

上海市浦东新区南汇精神卫生中心

具体地址:

上海市浦东新区拱乐路2759号

Institution
hospital:

Nanhui mental health center of Shanghai Pudong New Area

Address:

Nanhui mental health center of Shanghai Pudong New Area

经费或物资来源:

浦东新区卫生健康委员会

Source(s) of funding:

Health Commission of Pudong New Area

研究疾病:

药物依赖性失眠  

Target disease:

drug-dependent insomnia

研究疾病代码:

Target disease code:

研究类型:

干预性研究

Study type:

Interventional study

研究所处阶段:

I期临床试验 

Study phase:

1

研究设计:

随机平行对照 

Study design:

Parallel 

研究目的:

开展随机对照临床试验,采用国际通行的疗效评定标准进行疗效评价,观察电针结合艾司唑仑撤药与单纯艾司唑仑撤药对比观察,以明确电针在药物依赖性失眠方面的优势。  

Objectives of Study:

A randomized controlled clinical trial was conducted to evaluate the efficacy using the internationally accepted efficacy evaluation standard, and the comparative observation of electroacupuncture combined with the withdrawal of estazolam and the withdrawal of estazolam alone was observed to clarify the advantages of electroacupuncture in drug-dependent insomnia.

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

(1)年龄在18-70岁,
(2)符合失眠的中西医诊断标准,服用艾司唑仑1mg以上≥6个月;
(3)无严重器质性疾病如心血管疾病、肝肾功能不全以及精神病等;
(4)自愿签署知情同意书。

Inclusion criteria

(1)18 years old≤Age<70 years old;
(2) Patients who meet the diagnostic criteria of Chinese and Western medicine for insomnia, take more than 1mg of estazolam for ≥ 6 months
(3) No serious organic diseases such as cardiovascular disease, liver and kidney dysfunction and psychosis;
(4) Volunteer to participate in this study and sign informed consent.

排除标准:

(1)使用艾司唑仑以外的其它治疗失眠药物者;
(2)患有严重心、脑、肾、肝脏疾病患者; 合并有抑郁症、焦虑症、精神分裂症等严重精神疾病患者;
(3)有全身性疾病如疼痛、发热、咳嗽、手术等以及外界环境干扰因素引起的继发性失眠患者;
(3)酗酒或有其它物质依赖;
(4)治疗期间使用其它疗法导致疗效无法判定者。
(5)孕妇、哺乳期妇女、有皮肤过敏和针刺不良反应者;
(6)不良生活习惯(如吸烟、嗜酒、长时间玩电子产品等)影响睡眠者;

Exclusion criteria:

(1) Those who use other drugs for insomnia other than eszolam;
(2) Patients with severe heart, brain, kidney and liver diseases; Patients with depression, anxiety, schizophrenia and other serious mental diseases;
(3) Alcoholism or other material dependence;
(4) Those who use other therapies during the treatment period, resulting in failure to determine the efficacy.
(5) Pregnant women, lactating women, people with skin allergy and adverse reactions to acupuncture;
(6) Bad living habits (such as smoking, drinking, playing electronic products for a long time, etc.) affect sleepers;

研究实施时间:

Study execute time:

From 2022-12-01 00:00:00 To 2025-03-31 00:00:00  

征募观察对象时间:

Recruiting time:

From 2022-12-01 00:00:00 To 2024-09-30 00:00:00

干预措施:

Interventions:

组别:

治疗组

样本量:

30

Group:

treatment group

Sample size:

干预措施:

电针+减药法

干预措施代码:

Intervention:

electroacupuncture + medicine reducing method

Intervention code:

组别:

对照组

样本量:

30

Group:

control group

Sample size:

干预措施:

减药法

干预措施代码:

Intervention:

medicine reducing method

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

上海 

市(区县):

 

Country:

China

Province:

Shanghai

City:

单位(医院):

上海市浦东新区南汇精神卫生中心 

单位级别:

二级甲等 

Institution
hospital:

Nanhui mental health center of Shanghai Pudong New Area

Level of the institution:

Secondary A

测量指标:

Outcomes:

指标中文名:

减药量

指标类型:

主要指标

Outcome:

dosage reduction

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

匹兹堡睡眠质量指数

指标类型:

次要指标

Outcome:

PSQI

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

苯二氮卓戒断症状问卷

指标类型:

次要指标

Outcome:

BWSQ

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

血液

组织:

Sample Name:

blood

Tissue:

人体标本去向

使用后销毁  

说明

Fate of sample:

Destruction after use  

Note:

征募研究对象情况:

Recruiting status:

尚未开始

Not yet recruiting

年龄范围:

Participant age:

最小 Min age 18 years
最大 Max age 70 years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

入组前,研究者再次核对纳入及排除标准确认受试者是否入组。受试者筛选合格以后,研究人员根据入组顺序分配一个受试者编号即随机号,根据随机号拆除随机信封,根据随机信封组别和治疗方案给予受试者相应治疗。

Randomization Procedure (please state who generates the random number sequence and by what method):

The researchers assigned patients random numbers according to the enrollment order, removed the random envelope according to the random number, and gave corresponding treatment according to the random envelope group and treatment.

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

公开/Public

盲法:

Blinding:

试验完成后的统计结果(上传文件):

Calculated Results after
the Study Completed(upload file):

是否共享原始数据:

IPD sharing

否No

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

http://www.cnki.net/

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

http://www.cnki.net/

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

CRF

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

CRF

数据与安全监察委员会:

Data and Safety Monitoring Committee:

有/Yes

注册人:

Name of Registration:

 2022-11-23 16:31:01